Miyamoto Masakazu
Well-known member
MOA: H7N9 Subtype Avian Flu Vaccine to Be Put into Production for Use
Beijing, 19 Jun (Reporter: Chen Su)
Reporter learned from the Chinese Ministry of Agriculture (MOA) on the 19th, for the effective prevention and control of H7N9 subtype of avian influenza, MOA has been actively promoting scientific and technological research, and organized the National Avian Flu Reference Laboratory to carry out H7N9 poultry Influenza vaccine research. The National Avian Influenza Reference Laboratory used reverse genetic technology to build safe and efficient H7N9 inactivated vaccine production. After rigorous evaluation, new vaccine strains have no virulence to both poultry and mammals.
In order to avoid repeated injection of single vaccine, to reduce the number of poultry stress and epidemic prevention expenses, to realize on shot immunization of H5/H7 two subtype avian influenza epidemic strains for protection and control, China National Avian Influenza Reference Laboratory has successfully innovated (H5 + H7) bivalent inactivated vaccine, on the basis of original H5 recombinant avian influenza. Its protection rate of H5 and H7 subtype avian influenza was 100%, which provided a strong technical guarantee for effective prevention and control of avian influenza.
The Ministry of Agriculture completed H5-H7 divalent vaccine evaluation and issuing the technical standards, and organized enterprises to carry out vaccine production. In order to ensure the quality of the vaccine, it has made a series of arrangements on the strict issuance of management system, strengthening the electronic traceability management of vaccine products, supervision/inspection works and so on. The first batch of vaccines is expected to be delivered to Guangdong, Guangxi and other places at the end of June for immunization pilot work.
Source (Chinanews):
http://www.cneb.gov.cn/2017/06/19/ARTI1497886082378664.shtml
<< Mechanical T. >>
Ministry of Agriculture: H7N9 subtype avian influenza vaccine will be put into production use
Beijing, 19 Jun (Reporter Chen Rui) reporter learned from the Chinese Ministry of Agriculture on the 19th, for the effective prevention and control of H7N9 subtype of avian influenza, the Ministry of Agriculture to actively promote scientific and technological research, organization of the national avian flu reference laboratory to carry out H7N9 poultry Influenza vaccine research. The National Avian Influenza Reference Laboratory uses reverse genetic technology to build safe and efficient H7N9 inactivated vaccine production. After rigorous evaluation, new vaccine strains have no virulence to both poultry and mammals.
In order to avoid repeated injection of single vaccine, reduce the number of poultry stress and epidemic prevention expenses, to achieve an immunization at the same time prevention and control of H5 and H7 two subtype avian influenza epidemic strains of the purpose of China National Avian Influenza Reference Laboratory in the original H5 recombinant avian influenza (H5 + H7) bivalent inactivated vaccine, the protection rate of H5 and H7 subtype avian influenza was 100%, which provided a strong technique for the effective prevention and control of avian influenza. Guarantee.
14, the Ministry of Agriculture organized H5-H7 divalent vaccine evaluation and technical standards issued work, and organize enterprises to carry out vaccine production. In order to ensure the quality of the vaccine, it has made a series of arrangements on the strict issuance of management system, strengthening the electronic traceability management of vaccine products, supervision and inspection work. The first batch of vaccines is expected to be delivered to Guangdong, Guangxi and other places at the end of June for immunization pilot work.
Beijing, 19 Jun (Reporter: Chen Su)
Reporter learned from the Chinese Ministry of Agriculture (MOA) on the 19th, for the effective prevention and control of H7N9 subtype of avian influenza, MOA has been actively promoting scientific and technological research, and organized the National Avian Flu Reference Laboratory to carry out H7N9 poultry Influenza vaccine research. The National Avian Influenza Reference Laboratory used reverse genetic technology to build safe and efficient H7N9 inactivated vaccine production. After rigorous evaluation, new vaccine strains have no virulence to both poultry and mammals.
In order to avoid repeated injection of single vaccine, to reduce the number of poultry stress and epidemic prevention expenses, to realize on shot immunization of H5/H7 two subtype avian influenza epidemic strains for protection and control, China National Avian Influenza Reference Laboratory has successfully innovated (H5 + H7) bivalent inactivated vaccine, on the basis of original H5 recombinant avian influenza. Its protection rate of H5 and H7 subtype avian influenza was 100%, which provided a strong technical guarantee for effective prevention and control of avian influenza.
The Ministry of Agriculture completed H5-H7 divalent vaccine evaluation and issuing the technical standards, and organized enterprises to carry out vaccine production. In order to ensure the quality of the vaccine, it has made a series of arrangements on the strict issuance of management system, strengthening the electronic traceability management of vaccine products, supervision/inspection works and so on. The first batch of vaccines is expected to be delivered to Guangdong, Guangxi and other places at the end of June for immunization pilot work.
Source (Chinanews):
http://www.cneb.gov.cn/2017/06/19/ARTI1497886082378664.shtml
<< Mechanical T. >>
Ministry of Agriculture: H7N9 subtype avian influenza vaccine will be put into production use
Beijing, 19 Jun (Reporter Chen Rui) reporter learned from the Chinese Ministry of Agriculture on the 19th, for the effective prevention and control of H7N9 subtype of avian influenza, the Ministry of Agriculture to actively promote scientific and technological research, organization of the national avian flu reference laboratory to carry out H7N9 poultry Influenza vaccine research. The National Avian Influenza Reference Laboratory uses reverse genetic technology to build safe and efficient H7N9 inactivated vaccine production. After rigorous evaluation, new vaccine strains have no virulence to both poultry and mammals.
In order to avoid repeated injection of single vaccine, reduce the number of poultry stress and epidemic prevention expenses, to achieve an immunization at the same time prevention and control of H5 and H7 two subtype avian influenza epidemic strains of the purpose of China National Avian Influenza Reference Laboratory in the original H5 recombinant avian influenza (H5 + H7) bivalent inactivated vaccine, the protection rate of H5 and H7 subtype avian influenza was 100%, which provided a strong technique for the effective prevention and control of avian influenza. Guarantee.
14, the Ministry of Agriculture organized H5-H7 divalent vaccine evaluation and technical standards issued work, and organize enterprises to carry out vaccine production. In order to ensure the quality of the vaccine, it has made a series of arrangements on the strict issuance of management system, strengthening the electronic traceability management of vaccine products, supervision and inspection work. The first batch of vaccines is expected to be delivered to Guangdong, Guangxi and other places at the end of June for immunization pilot work.